Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate the development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development. Verge has pioneered the industry's most advanced all-in-human, artificial intelligence-powered drug discovery platform to unlock new drugs at scale for the biggest medical challenges of our time.

Our mission is to develop better drugs and faster-using technology. Verge was born from the convergence of multiple technological forces, including human genomics, machine learning, biological engineering, and translational medicine, that are enabling us to decipher biology. Instead of using animal or cell models, we have built one of the world's largest proprietary multi-omics databases directly from human tissue. We use machine learning to map the complex causes of disease and develop those insights into proprietary drug candidates on our internal biology and chemistry platforms. We are developing drugs to treat the biggest medical challenges of our generation. Our first drug is anticipated to enter the clinic this year for ALS and was discovered entirely from our platform. We are working on a dozen breakthrough opportunities for Parkinson's Disease, Frontotemporal Dementia, and other devastating diseases with no effective treatments to date.